Patel A, Haleem A, Revercomb L, Brant J, Rajasekaran K, Sun L
Laryngoscope Investig Otolaryngol. 2024; 9(5):e70000.
PMID: 39281203
PMC: 11401054.
DOI: 10.1002/lio2.70000.
Fujimoto T, Yamasaki O, Kanehira N, Matsushita H, Sakurai Y, Kenmotsu N
Cancer Sci. 2024; 115(10):3231-3247.
PMID: 39119813
PMC: 11447877.
DOI: 10.1111/cas.16298.
Li R, Cheng K, Li X, Chang C, Lv W, Xiaoying L
Front Pharmacol. 2023; 14:1147449.
PMID: 37614316
PMC: 10443589.
DOI: 10.3389/fphar.2023.1147449.
Li L, Chen L, Yan L, Guo Y, Li F, Fan M
Radiat Oncol. 2023; 18(1):109.
PMID: 37403098
PMC: 10318764.
DOI: 10.1186/s13014-023-02310-8.
Hatten Jr S, Lehrer E, Liao J, Sha C, Trifiletti D, Siva S
Adv Radiat Oncol. 2022; 7(3):100909.
PMID: 35372719
PMC: 8971834.
DOI: 10.1016/j.adro.2022.100909.
Interpretation of 2-[F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.
Manson G, Lemchukwu A, Mokrane F, Lopci E, Aide N, Vercellino L
Eur Radiol. 2022; 32(9):6536-6544.
PMID: 35344061
DOI: 10.1007/s00330-022-08669-8.
Lumpectomy followed by radiation improves survival in HER2 positive and triple-negative breast cancer with high tumor-infiltrating lymphocytes compared to mastectomy alone.
Mouabbi J, Chand M, Asghar I, Sakhi R, Ockner D, Dul C
Cancer Med. 2021; 10(14):4790-4795.
PMID: 34080777
PMC: 8290225.
DOI: 10.1002/cam4.4050.
Carbon Ion Radiobiology.
Tinganelli W, Durante M
Cancers (Basel). 2020; 12(10).
PMID: 33080914
PMC: 7603235.
DOI: 10.3390/cancers12103022.
Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy.
Castellanos E, Feld E, Estrada M, Sanders M, Massion P, Johnson D
JCO Precis Oncol. 2020; 1.
PMID: 32913978
PMC: 7446533.
DOI: 10.1200/PO.17.00049.
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma.
Boutros C, Chaput-Gras N, Lanoy E, Larive A, Mateus C, Routier E
J Immunother Cancer. 2020; 8(2).
PMID: 32819972
PMC: 7443273.
DOI: 10.1136/jitc-2020-000627.
The changing role of radiation therapy in the management of oligometastatic disease.
Tharmalingham H, Hoskin P
Tech Innov Patient Support Radiat Oncol. 2020; 1:13-15.
PMID: 32095538
PMC: 7033765.
DOI: 10.1016/j.tipsro.2017.01.001.
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.
Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M
Mol Ther. 2020; 28(3):794-804.
PMID: 31991110
PMC: 7054725.
DOI: 10.1016/j.ymthe.2020.01.003.
Cytoreductive treatment strategies for de novo metastatic prostate cancer.
Connor M, Shah T, Horan G, Bevan C, Winkler M, Ahmed H
Nat Rev Clin Oncol. 2019; 17(3):168-182.
PMID: 31712648
DOI: 10.1038/s41571-019-0284-3.
Harnessing radiation to improve immunotherapy: better with particles?.
Durante M, Formenti S
Br J Radiol. 2019; 93(1107):20190224.
PMID: 31317768
PMC: 7066943.
DOI: 10.1259/bjr.20190224.
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A
J Immunother Cancer. 2019; 7(1):160.
PMID: 31238970
PMC: 6593525.
DOI: 10.1186/s40425-019-0634-9.
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment.
Menon H, Ramapriyan R, Cushman T, Verma V, Kim H, Schoenhals J
Front Immunol. 2019; 10:193.
PMID: 30828330
PMC: 6384252.
DOI: 10.3389/fimmu.2019.00193.
Pneumonitis in Combined Anti-programmed Death-1 Immunotherapy and Radiation Therapy for Renal Cell Carcinoma.
Yu N, Deftos M, Wang C
Cureus. 2019; 10(12):e3748.
PMID: 30820369
PMC: 6388854.
DOI: 10.7759/cureus.3748.
Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.
Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S
J Gastrointest Oncol. 2019; 9(6):1014-1026.
PMID: 30603120
PMC: 6286952.
DOI: 10.21037/jgo.2018.05.16.
Future cancer research priorities in the USA: a Lancet Oncology Commission.
Jaffee E, Van Dang C, Agus D, Alexander B, Anderson K, Ashworth A
Lancet Oncol. 2017; 18(11):e653-e706.
PMID: 29208398
PMC: 6178838.
DOI: 10.1016/S1470-2045(17)30698-8.
The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto P, Jiang W, Brown P, Braunstein S, Sneed P, Wattson D
Int J Radiat Oncol Biol Phys. 2017; 98(5):1069-1077.
PMID: 28721890
PMC: 6925531.
DOI: 10.1016/j.ijrobp.2017.03.030.
